Survey responses indicate that bio/pharma faces tariff-driven rising costs and supply strain, with firms aiming to boost compliance and diversification and seeking stable trade and R&D support.

Orlynvah is the first new, branded product for the treatment of uncomplicated UTIs to be introduced in the US in more than 25 years.

The guidance document provides recommendations for identifying an optimized dosage for radiopharmaceutical therapies for ...

FDA’s recommendation to control 7-OH products under the Controlled Substances Act should help prevent competition between ...

Pharmaceutical Technology® spoke with C. Michael White, distinguished professor and Chair of the Department of Pharmacy Practice at the UConn School of Pharmacy and chair of the Kratom Consumer ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...

Based on an analysis done by the European Medicines Agency on the feasibility of alternatives, the European Commission ...

Dave Miller, PhD, explains how early formulation planning, novel platforms, and tailored approaches secure long-term protection against generics.

Dave Miller, PhD, discusses how shifting drug manufacturing to domestic CDMOs can improve quality, reduce rework, and enhance ...

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...

Experts from LGM Pharma and Rockwell Automation share their thoughts on what makes tech transfer effective, where processes ...